RxDoctor Payments Data

Robert Black, MD

Hematology & Oncology · Bristol, CTNPI 1457644668

Payments from drug & device makers

$6,948in general payments, 2019–2025

Across 35 payments — averaging $198.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Seagen Inc.$131
  • Sobi, Inc$125
  • Pharmacosmos Therapeutics Inc.$64
  • Genentech USA, Inc.$62
  • Bristol Myers Squibb$44
  • plus $147 from 6 others

What the payments were for

  • Consulting fees$3505%
  • Speaking & faculty fees$4,67167%
  • Travel & lodging$1,04415%
  • Food & beverage$6569%
  • Education$2283%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,948 in reported general payments places this provider in the 50th percentile of 163 hematology & oncology providers in Connecticut.

See all hematology & oncology providers in Connecticut

Medicare billing

Part B allowed, 2024
$58,155
Medicare patients
192
Services billed
558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide52$927,473
Abiraterone Acetate100$401,708
ImbruvicaIbrutinib11$209,336
MekinistTrametinib Dimethyl Sulfoxide12$189,573
ErleadaApalutamide12$179,686
TafinlarDabrafenib Mesylate12$174,606
EliquisApixaban110$144,759
XareltoRivaroxaban69$97,740
Cyclosporine17$13,063
VeozahFezolinetant12$7,782
Ondansetron Hcl13$5,825
Letrozole68$2,241
Anastrozole149$1,829
Ondansetron OdtOndansetron31$1,208
Prochlorperazine Maleate30$1,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$44$927,47352 claims
PfizerEliquis$37$144,759110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 163 hematology & oncology providers in Connecticut.

Other hematology & oncology in Bristol

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →